High prevalence of ghost authorship in industry-initiated trials
This article has no abstract so we have provided the first paragraph of the full text.
In a Danish cohort study, Gøtzsche et al. have investigated the prevalence of 'ghost authorship' in industry-initiated clinical trials. They defined a 'ghost author' as an individual who contributed to statistical analysis or to the writing of the trial protocol or published manuscript without being identified as an author, as a member of a study group or writing committee, or in the acknowledgments section. By examining original full trial protocols and subsequent primary papers, the authors found evidence of ghost authorship in 33 of 44 (75%) industry-initiated trials that received approval in the period 1994–1995 (data published 1997–2002). This is in contrast to the results of self-reporting surveys on ghost authorship, which have estimated prevalences of 10–15%.
Full text of this article is available with one of the following:
- Membership of the International Society of Nephrology. If already a member, please login. If not please join the Society now
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please login for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or login above.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
